This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2021
  • /
  • 6
  • /
  • CASSIOPEIA phase III study of Darzalex + Velcade +...

CASSIOPEIA phase III study of Darzalex + Velcade + Thalomid + dexamthasone shows efficacy in multiple myeloma.- Genmab

Read time: 1 mins
Published:13th Jun 2021
Part 1 of the CASSIOPEIA phase III study compared the addition of Darzalex (daratumumab), from Genmab, to Velcade (bortezomib), Thalomid (thalidomide), and dexamethasone (D-VTd) induction/consolidation with VTd alone in transplant-eligible patients with newly diagnosed multiple myeloma.

The results of the study showed superior efficacy of D-VTd over VTd alone in combination with autologous stem cell transplantation (ASCT), which led to the regulatory approval of the treatment. The results from the CASSIOPEIA part 2 interim analysis aimed to compare daratumumab maintenance (16 mg/kg every 8 weeks) with observation treatment in all 886 responders from part 1 of the study. The interim analysis showed that patients maintained with daratumumab exhibited significantly longer progression-free survival (PFS) compared to the observation treatment arm. However, stratification of the patients by induction/consolidation treatment revealed that this benefit only appeared in patients previously treated with VTd in CASSIOPEIA part 1. Patients who received D-VTd in part 1 and were placed on daratumumab maintenance showed comparable PFS to the observation group. Furthermore, daratumumab maintenance led to a significantly higher depth of response and no new safety signals were detected. In summary, daratumumab maintenance is beneficial for patients after ASCT who received VTd induction/consolidation.

Condition: Multiple Myeloma
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.